comparemela.com

Latest Breaking News On - Sarah mathieson - Page 3 : comparemela.com

Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Sylvia wheelerDavid coryBristol myers squibbSarah mathiesonPrnewswire eiger biopharmaceuticals incEuropean medicines agencyDrug administrationEiger biopharmaceuticals incCorporate affairsTreated withinOrphan designationFast trackBreakthrough therapy designationData safety monitoring boardPrivate securities litigation reform actQuarterly report

Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

New yorkUnited statesSylvia wheelerSarah mathiesonEiger biopharmaceuticals incCorporate affairsEiger biopharmaceuticalsAnnual biopharmaAnnual global investment

Eiger BioPharmaceuticals, Inc (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call Transcript

Eiger BioPharmaceuticals, Inc. (NASDAQ:NASDAQ:EIGR) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory -.

United statesCity ofUnited kingdomSriram ryaliMichael higginsDavid corySarah mathiesonBrian skorneyColin hislopIngrid choongRobert hazlettJeffrey glennEldon mayerMaurice raycroftYigal nochomovitzColleen craig

Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Sylvia wheelerLisa kelly croswellProgeroid laminopathiesDavid corySarah mathiesonCompany annualNational institutes of healthEuropean commissionDrug administrationPrnewswire eiger biopharmaceuticals incEiger biopharmaceuticals incAnges incCorporate affairsActive dialoguePotential peginterferon lambdaStudy topline data planned

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Sylvia wheelerSarah mathiesonPrnewswire eiger biopharmaceuticals incEiger biopharmaceuticals incCorporate affairsConference callLife science advisors

vimarsana © 2020. All Rights Reserved.